Our pipeline is focused on licensing a wide range of medicines that currently fall short of patient needs, and we work closely with payors to meet volume requirements. We are fully committed to addressing the expectations of both you and your patients, while continuously exploring new product opportunities.

As we evolve at a rapid pace, both our UK and EU Distribution Hubs are in development, with ambitious growth plans on the horizon. We anticipate having all licenses secured by Q4 2024, setting the stage for even greater advancements.